Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Subunit vaccine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    70 result(s) found for: Subunit vaccine. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-004550-33 Sponsor Protocol Number: APHP211184 Start Date*: 2021-11-15
    Sponsor Name:Assistance publique Hopitaux de Paris/ DRCI
    Full Title: Immunogenicity and reactogenicity following a booster dose of COVID-19 mRNA vaccine (Pfizer-BioNtech) and two adjuvanted sub-unit vaccines (SP/GSK) administered in adults who received 2 doses of Pf...
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004498-17 Sponsor Protocol Number: V71_18 Start Date*: 2014-11-13
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Multi-center, Phase III, Randomized, Observer Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Trivalent Subunit Inactivated Influenza Vaccine (Agriflu™) in Healthy Child...
    Medical condition: Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-000881-12 Sponsor Protocol Number: M13-998 Start Date*: 2013-07-11
    Sponsor Name:Abbott Biologicals B.V
    Full Title: Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Northern Hemisphere Season 2013/2014. An Open-Label, Baseline- Controlled Study in Two Age Gro...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000101-54 Sponsor Protocol Number: 8162 Start Date*: 2006-02-10
    Sponsor Name:University Hospitals Leicester, Leicester General Hospital
    Full Title: A randomized, observer-blind, dose-ranging, single-centre, study to evaluate the safety, tolerability and immunogenicity of adjuvanted and non-adjuvanted influenza A/Hong Kong/1073/99 (H9N2) vaccin...
    Medical condition: Vaccine study to assess the safety and immunogenicity of whole virus, alum-adjuvanted whole virus and virosomal A/HongKong/1073/99 (H9N2) vaccine in healthy adult volunteers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002872-32 Sponsor Protocol Number: V58P14 Start Date*: 2007-11-01
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase IV, Multi-Center, Active-Controlled, Observer-Blind Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture (Optaflu®) or in Embryona...
    Medical condition: no medical condition: healthy subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005558-63 Sponsor Protocol Number: V70P3 Start Date*: 2006-11-28
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A phase III, randomized, controlled, observer-blind, single-center study to compare immunogenicity and safety of an MF59-adjuvanted inactivated subunit influenza vaccine (FLUAD™) to those of a nona...
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001223-13 Sponsor Protocol Number: V58_31 Start Date*: 2014-12-03
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in Embryonated Ch...
    Medical condition: Prophylaxis: Influenza
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001032-57 Sponsor Protocol Number: M13-567 Start Date*: 2012-06-26
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Northern Hemisphere Season 2012/2013. An Open-Label, Baseline- Controlled Study in Two Age ...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002257-47 Sponsor Protocol Number: V58P9 Start Date*: 2005-08-24
    Sponsor Name:Chiron S.r.l.
    Full Title: A Phase III, Randomized, Controlled, Observer-Blind, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of Three Lots of Trivalent Subunit Influen...
    Medical condition: Influenza
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002871-15 Sponsor Protocol Number: V58P13 Start Date*: 2007-09-14
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine i...
    Medical condition: Influenza disease.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-013639-39 Sponsor Protocol Number: V110_03 Start Date*: 2009-07-29
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Cell-Derived, Inactivated Novel Swine ...
    Medical condition: Pandemic influenza
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001404-20 Sponsor Protocol Number: V58P1S Start Date*: 2007-05-14
    Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG
    Full Title: A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of a single intramuscular dose of a trivalent subunit influenza vaccine produced in mammalian cell cul...
    Medical condition: No medical condition; healthy volunteers will be recruited into clinical trial for annual approval of Influenza vaccine with new strain composition according to WHO and EMEA recommendation and CPMP...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013671-21 Sponsor Protocol Number: V111_02 Start Date*: 2009-08-27
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Egg-Derived, Inactivated Novel Swine O...
    Medical condition: Pandemic influenza
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005107-24 Sponsor Protocol Number: V112_06 Start Date*: 2014-12-04
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1) 2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months
    Medical condition: Prophylaxis of A (H1N1) 2009 Pandemic Influenza
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000875-40 Sponsor Protocol Number: S201.3.126 Start Date*: 2007-05-25
    Sponsor Name:Solvay Pharmaceuticals B.V.
    Full Title: Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac® for the season 2007/2008. An open, baseline-controlled multi-centre study in two groups of healthy subjects: ...
    Medical condition: Prophylaxis of influenza.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001300-37 Sponsor Protocol Number: S201.3.125 Start Date*: 2006-07-11
    Sponsor Name:Solvay Pharmaceuticals B.V.
    Full Title: Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac® for the season 2006/2007. An open, baseline-controlled study in two groups of healthy subjects: adult subjects...
    Medical condition: Prophylaxis of influenza, especially in those who run an increased risk of associated complications.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000133-70 Sponsor Protocol Number: V130_03 Start Date*: 2015-01-09
    Sponsor Name:Novartis Vaccines and Diagnostics, Inc
    Full Title: A Phase III, Stratified, Randomized, Double-Blind, Multicenter, Non-Inferiority Study to Evaluate Safety and Immunogenicity of Cell-Based Quadrivalent Subunit Influenza Virus Vaccine and Cell-Based...
    Medical condition: Prophylaxis of A Three Influenza Vaccines in Children Ages 4 Years Old to Less Than 18 Years Old
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005106-38 Sponsor Protocol Number: V112_02 Start Date*: 2014-12-04
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Pivotal Randomized, Single-Blind, Dose-Finding Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Nov...
    Medical condition: Prophylaxis of A (H1N1) 2009 Pandemic Influenza
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000944-13 Sponsor Protocol Number: GEN-004-002 Start Date*: 2014-07-30
    Sponsor Name:Genocea Biosciences, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intran...
    Medical condition: Pneumococcal Nasal Carriage
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10069594 Pneumococcal immunization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005128-91 Sponsor Protocol Number: V71_21 Start Date*: 2014-11-26
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: Evaluating the safeness of Agrippal® S1 in preventing flu on Vietnamese volunteers.
    Medical condition: Prophylaxis for seasonal flu.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 06:27:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA